Stratum Nutrition is a specialty health ingredient supplier to the supplement and pet food industries. Stratum Nutrition offers a portfolio of branded, value-added ingredients developed in collaboration with global partnerships, based on consumer need, and supported by science. Stratum Nutrition specializes in condition-specific categories that included structural, digestive, and immune health to offer full solutions for human and companion animal nutrition. Leveraging the Novus core competencies in nutritional research and innovation, these ingredients are progressive, safe and reliable.
Improving Human Health with Egg-Derived Ingredients
We maintain our strong focus on egg-derived nutritional ingredients based on eggshell membrane and our subsidiary, ESM Technologies, LLC, has continued to expand NEM® in several countries around the globe, including new international sales in Turkey, Germany, Australia and New Zealand and more. This is opening up new opportunities to make a difference to the quality of life those with joint pain or motoric difficulties. In 2013, we continued to invest in research and completed two more clinical trials to demonstrate different aspects of NEM® and expect the positive results to be published in 2014.
Meeting Customer Preferences
We continuously strive to create new delivery formats for our egg-derived wellness ingredients to meet the needs of our customers. Swallowing capsules can be difficult for some consumers, so different formats are needed to make our ingredients more palatable and acceptable to consumers. One of our most recent developments is a cherry-flavored soft chew featuring its NEM® brand eggshell membrane ingredient for joint health.
ESM Technologies partnered with Nutravail Technologies, specialists in developing nutraceutical ingredients in great-tasting formats, to develop a soft chew which incorporates NEM® into a quality, tasty product in a form that consumers like and prefer over capsule form. Creating different delivery options helps our customers understand the multiple possibilities of inclusion of our ingredients as they develop new products to meet consumer needs. We continue to work on developing other delivery format prototypes and hope to expand the options for NEM® delivery even further in the coming year for the benefit of even more consumers.
Collaboration for Innovation
As a small company and part of Novus, ESM Technologies has come to understand the value of partnerships and collaboration with other organizations in a way that delivers mutual benefits. That is why, in 2013, ESM Technologies became a corporate affiliate member of the Jordan Valley Innovation Center (JVIC). The JVIC provides a framework in which we can continue to conduct our advanced research and development onto our unique products while benefiting from access to modern facilities, equipment, laboratory resources, research interns and non-competitive collaborative relationships which can help us become more effective and innovative as we develop new egg-derived products and applications. As an affiliate, we commit to conducting our research through the JVIC network and playing an active role in helping determine how resources are most effectively utilized for the benefit of all.
Advancing Oral Health
In 2013, we continued to promote benefits of our oral health probiotics, and in early 2013 announced the publication of new studies evaluating BLIS K12® oral probiotic and recurrent pharyngitis and tonsillitis. The independent studies were published in the International Journal of General Medicine and Expert Opinion on Biological Therapy with encouraging findings in both children and adults. One independent research study evaluated the effectiveness of BLIS K12® oral probiotic for supporting ear and throat health in children, demonstrating that they could minimize the re-occurrence of common childhood ear and throat infections, such as otitis media and tonsillitis by around 40 and 90 percent respectively.
Another clinical study further supports the findings of BLIS K12® oral cavity probiotic for supporting ear and throat health, which demonstrated a reduction in the reoccurrence of common ear and throat infections, such as strep throat infection and tonsillitis by more than 83 percent in adults. The study followed 40 adults with a history of recurrent ear and throat infection and examined the effect of 90 days of treatment with either the BLIS K12® probiotic or a placebo. Researchers concluded “The regular use of BLIS K12® appears to have effected a substantial reduction in the incidence of recurrent oral streptococcal pathology, reducing the requirement for these BLIS K12-treated individuals to be exposed to therapeutic courses of antibiotics.”
In the light of these results, we have seen great interest from pediatricians and oral health experts, and the first products containing BLIS K12® in different countries have started to be marketed. We believe this product makes a significant contribution to human health and wellness and continue to support our customers as they formulate different products with this uniquely effective probiotic.